Screening studies indicate a worldwide incidence of classical 21-hydroxylase-deficient CAH as 1 in 13,000 to 1 in 54,000 live births.[2] National Newborn Screening Information System (NNSIS) external link opens in a new window Incidences vary among different populations, ranging from 1 in 600 live births in Yupik Eskimos of Alaska, to 1 in 5000 live births in Saudi Arabia, to 1 in 23,000 live births in New Zealand. The prevalence frequency of non-classical 21-hydroxylase-deficient CAH is considerably higher, at 1 in 1000, in white populations, with an even higher frequency among selected ethnic groups - most notably, Ashkenazi Jews.[3][4] Prevalence of non-classical CAH is 1 in 27 Ashkenazi Jews, 1 in 40 Hispanics, 1 in 50 Yugoslavs, 1 in 300 Italians, and 1 in 100 in a heterogeneous New York population.[3][4] Additionally, there is a high frequency of CAH due to 21-hydroxylase deficiency among Yupik Eskimos of southwestern Alaska (1 in 282).[5] The fertility rate among untreated females with non-classical CAH is reported to be 50%.[6]

BMJ Best Practice is an evidence-based point of care tool for healthcare practitioners.

To continue reading and access all of BMJ Best Practice's pages you'll need to log in or start a free trial.

You can access through your institution if your hospital, university, trust or other institution provides access to BMJ Best Practice through either OpenAthens or Shibboleth.

Use of this content is subject to our disclaimer